Hematogenix is a global cancer-focused life science company catering to the pharmaceutical & biotechnology industry and community physicians. The company boasts a team of passionate scientists, board-certified clinical and anatomic pathologists, and hematopathologists from around the world, offering a range of biomarker development and testing services for navigating the complexities of human diseases and clinical trials.
Operating across the US, Europe, China, and Asia-Pacific, Hematogenix provides reference laboratory services, uniquely positioned to support clients in accelerating cancer research and drug development efforts across its globally connected facilities.
Services offered by Hematogenix include Flow Cytometry, Molecular Genetics, Next Generation Sequencing (NGS), Histology/Immunohistochemistry (IHC), Cytogenetics/FISH, Pathology, Digital Pathology, and Image Analysis, reflecting the company's commitment to utilizing advanced techniques to enhance patient care. The company also offers customized services from the initial stages of research to development, extending to the implementation of targeted therapies in the clinical setting. Furthermore, Hematogenix holds accreditations including CAP, CLIA certification, and GCP compliance, ensuring high-quality standards in its operations. Founded in 2007, Hematogenix operates within the pharmaceutical industry.
Currently, there is no publicly available information about Hematogenix's last investment or investors.
There is no investment information
No recent news or press coverage available for Hematogenix.
We care about your data, and we'd love to use cookies make your experience better.
